Scarica l'app Stockscreener
34.31
2.76%
0.92
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché HRMY Giù?
Forum
Previsione
Precedente Chiudi:
$33.39
Aprire:
$33.32
Volume 24 ore:
777.65K
Relative Volume:
0.86
Capitalizzazione di mercato:
$1.98B
Reddito:
$772.53M
Utile/perdita netta:
$180.90M
Rapporto P/E:
11.06
EPS:
3.1024
Flusso di cassa netto:
$258.73M
1 W Prestazione:
+0.82%
1M Prestazione:
+31.15%
6M Prestazione:
-0.55%
1 anno Prestazione:
+3.25%
Intervallo 1D:
$33.21
$35.00
Intervallo di 1 settimana:
$32.77
$35.00
Portata 52W:
$25.52
$40.93
Harmony Biosciences Holdings Inc Stock (HRMY) Company Profile
Nome
Harmony Biosciences Holdings Inc
Settore
Industria
Telefono
(484) 539-9800
Indirizzo
630 W GERMANTOWN PIKE, PLYMOUTH MEETING
Confronta HRMY con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
HRMY
Harmony Biosciences Holdings Inc
|
34.31 | 1.92B | 772.53M | 180.90M | 258.73M | 3.1024 |
|
VRTX
Vertex Pharmaceuticals Inc
|
426.76 | 107.15B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
755.90 | 77.46B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
436.38 | 58.90B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
918.92 | 56.55B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
198.76 | 42.58B | 447.02M | -1.18B | -906.14M | -6.1812 |
Harmony Biosciences Holdings Inc Stock (HRMY) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-07-21 | Iniziato | Truist | Buy |
| 2025-07-10 | Ripresa | Goldman | Neutral |
| 2025-06-02 | Ripresa | Oppenheimer | Outperform |
| 2025-02-11 | Iniziato | Deutsche Bank | Buy |
| 2024-12-17 | Iniziato | H.C. Wainwright | Buy |
| 2024-10-10 | Ripresa | Raymond James | Outperform |
| 2024-09-10 | Iniziato | UBS | Buy |
| 2024-06-21 | Iniziato | Citigroup | Buy |
| 2024-01-02 | Downgrade | BofA Securities | Neutral → Underperform |
| 2023-09-25 | Downgrade | Goldman | Neutral → Sell |
| 2023-09-07 | Iniziato | Berenberg | Buy |
| 2023-04-20 | Iniziato | BofA Securities | Neutral |
| 2022-10-14 | Aggiornamento | Janney | Neutral → Buy |
| 2022-10-14 | Aggiornamento | Jefferies | Hold → Buy |
| 2022-08-03 | Downgrade | Jefferies | Buy → Hold |
| 2022-07-13 | Downgrade | Goldman | Buy → Neutral |
| 2022-07-07 | Iniziato | Mizuho | Buy |
| 2022-04-14 | Iniziato | Cantor Fitzgerald | Overweight |
| 2021-12-01 | Iniziato | Oppenheimer | Outperform |
| 2021-11-04 | Iniziato | Raymond James | Outperform |
| 2021-09-23 | Iniziato | Needham | Buy |
| 2021-03-29 | Aggiornamento | Goldman | Neutral → Buy |
| 2020-09-14 | Iniziato | Goldman | Neutral |
| 2020-09-14 | Iniziato | Jefferies | Buy |
| 2020-09-14 | Iniziato | Piper Sandler | Overweight |
Mostra tutto
Harmony Biosciences Holdings Inc Borsa (HRMY) Ultime notizie
Is Harmony Biosciences Holdings Inc. stock supported by strong cash flows2025 Technical Overview & Smart Investment Allocation Tips - newser.com
A Piece Of The Puzzle Missing From Harmony Biosciences Holdings, Inc.'s (NASDAQ:HRMY) 28% Share Price Climb - simplywall.st
Harmony Biosciences Announces Initiation of First-In-Human Study With Potential Best-In-Class Orexin 2 Receptor Agonist (BP1.15205) for Central Disorders of Hypersomnolence - BioSpace
What insider trading reveals about Harmony Biosciences Holdings Inc. stockEarnings Growth Report & Low Risk Entry Point Guides - newser.com
Harmony Advances First Human Study of Orexin 2 Agonist - Sleep Review
Why Harmony Biosciences Holdings Inc. stock is favored by top institutionsInsider Buying & Safe Capital Investment Plans - newser.com
Why Harmony Biosciences Holdings Inc. stock could benefit from AI revolution - newser.com
Harmony Biosciences Initiates Patient Dosing in BP1.15205 Study for Central Disorders of Hypersomnolence - MarketScreener
Using Ichimoku Cloud for Harmony Biosciences Holdings Inc. technicalsWeekly Trade Recap & AI Based Buy/Sell Signal Reports - newser.com
Harmony Biosciences to Participate in Upcoming Investor Conferences - Business Wire
(HRMY) Risk Channels and Responsive Allocation - news.stocktradersdaily.com
Harmony Biosciences reports Q3 revenue of $239M, raises FY25 revenue guidance - MSN
What technical signals suggest for Harmony Biosciences Holdings Inc. stockForecast Cut & AI Forecast Swing Trade Picks - newser.com
Harmony Biosciences Surges on Strong WAKIX Growth as Cash Position Climbs to $778M - MyChesCo
How interest rate cuts could boost Harmony Biosciences Holdings Inc. stockEarnings Recap Report & Daily Market Momentum Tracking - newser.com
Will Harmony Biosciences Holdings Inc. stock gain from lower inflation2025 Market Outlook & Long Hold Capital Preservation Tips - newser.com
Will Harmony Biosciences Holdings Inc. outperform the marketGlobal Markets & High Win Rate Trade Alerts - newser.com
Is Harmony Biosciences Holdings Inc. stock a top momentum play2025 Market Outlook & Stepwise Entry and Exit Trade Signals - newser.com
Sector ETF performance correlation with Harmony Biosciences Holdings Inc.2025 Market Sentiment & Free Reliable Trade Execution Plans - newser.com
Is Harmony Biosciences Holdings Inc. stock safe for conservative investorsInsider Buying & Momentum Based Trading Signals - Fundação Cultural do Pará
Forecasting Harmony Biosciences Holdings Inc. price range with options dataWeekly Trade Summary & Stepwise Entry and Exit Trade Signals - newser.com
Deutsche Bank Raises Price Target on Harmony Biosciences to $47 From $36, Keeps Buy Rating - MarketScreener
Harmony Biosciences Holdings, I (HRMY) Stock Forecasts - Yahoo Finance
Using Python tools to backtest Harmony Biosciences Holdings Inc. strategiesWeekly Trend Recap & Verified Stock Trade Ideas - newser.com
Will Harmony Biosciences Holdings Inc. stock reach all time highs in 2025 - newser.com
Harmony Biosciences Holdings Inc Azioni (HRMY) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.38%
1.42%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):